Viêm gan tự miễn: Tự kháng thể trong huyết thanh trong thực hành lâm sàng

Mieli-Vergani G, Vergani D, Czaja AJ et al (2018) Autoimmune hepatitis. Nat Rev Dis Primers 4:18017. https://doi.org/10.1038/nrdp.2018.17 Liberal R, Grant CR, Mieli-Vergani G, Vergani D (2013) Autoimmune hepatitis: a comprehensive review. J Autoimmun 41:126–139. https://doi.org/10.1016/j.jaut.2012.11.002 Lv T, Li M, Zeng N et al (2019) Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol 34:1676–1684. https://doi.org/10.1111/jgh.14746 European Association for the Study of the Liver (2015) EASL Clinical practice guidelines: autoimmune hepatitis. J Hepatol 63:971–1004. https://doi.org/10.1016/j.jhep.2015.06.030 Mack CL, Adams D, Assis DN et al (2020) Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the american association for the study of liver diseases. Hepatology 72:671–722. https://doi.org/10.1002/hep.31065 Soloway RD, Summerskill WH, Baggenstoss AH et al (1972) Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 63:820–833 Murray-Lyon IM, Stern RB, Williams R (1973) Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1:735–737 Cook GC, Mulligan R, Sherlock S (1971) Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 40:159–185 Di Giorgio A, Hadzic N, Dhawan A et al (2020) Seamless management of juvenile autoimmune liver disease: long-term medical and social outcome. J Pediatr 218:121-129.e3. https://doi.org/10.1016/j.jpeds.2019.11.028 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D (2018) The clinical usage and definition of autoantibodies in immune-mediated liver disease: a comprehensive overview. J Autoimmun. https://doi.org/10.1016/j.jaut.2018.10.004 Vergani D, Alvarez F, Bianchi FB et al (2004) Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 41:677–683. https://doi.org/10.1016/j.jhep.2004.08.002 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D et al (2019) The challenges of primary biliary cholangitis: what is new and what needs to be done. J Autoimmun 102328. https://doi.org/10.1016/j.jaut.2019.102328 Gatselis N, Zachou K, Montano-Loza A et al (2020) Antimitochondrial antibodies in patients with autoimmune hepatitis: a large multicenter study. J Hepatol 73:S471. https://doi.org/10.1016/S0168-8278(20)31423-9 Galaski J, Weiler-Normann C, Schakat M et al (2021) Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing. J Hepatol 74:312–320. https://doi.org/10.1016/j.jhep.2020.07.032 IanR M, Taft LI, Cowling DC (1956) Lupoid hepatitis. The Lancet 268:1323–1326. https://doi.org/10.1016/S0140-6736(56)91483-0 Tan EM, Feltkamp TEW, Smolen JS et al (1997) Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 40:1601–1611. https://doi.org/10.1002/art.1780400909 Hilário MOE, Len CA, Roja SC et al (2004) Frequency of antinuclear antibodies in healthy children and adolescents. Clin Pediatr (Phila) 43:637–642. https://doi.org/10.1177/000992280404300709 Buchner C, Bryant C, Eslami A, Lakos G (2014) Anti-nuclear antibody screening using HEp-2 cells. JoVE 51211. https://doi.org/10.3791/51211 Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69:1420–1422. https://doi.org/10.1136/ard.2009.127100 Andrade LEC, Klotz W, Herold M et al (2018) International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. Clin Chem Lab Med. https://doi.org/10.1515/cclm-2018-0188 Schramm C, Herkel J, Beuers U et al (2006) Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 101:556–560. https://doi.org/10.1111/j.1572-0241.2006.00479.x Liberal R, Mieli-Vergani G, Vergani D (2013) Clinical significance of autoantibodies in autoimmune hepatitis. J Autoimmun 46:17–24. https://doi.org/10.1016/j.jaut.2013.08.001 Villalta D, Girolami E, Alessio MG et al (2016) Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis. J Clin Lab Anal 30:41–46. https://doi.org/10.1002/jcla.21813 Dalekos GN, Gatselis NK, Zachou K, Koukoulis GK (2020) NAFLD and autoimmune hepatitis: do not judge a book by its cover. Eur J Intern Med 75:1–9. https://doi.org/10.1016/j.ejim.2020.02.001 Sebode M, Weiler-Normann C, Liwinski T, Schramm C (2018) Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol 9:609. https://doi.org/10.3389/fimmu.2018.00609 Bogdanos DP, Mieli-Vergani G, Vergani D (2009) Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 29:241–253. https://doi.org/10.1055/s-0029-1233533 Bogdanos D-P, Invernizzi P, Mackay I-R, Vergani D (2008) Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 14:3374–3387 Terziroli Beretta-Piccoli B, Ripellino P, Gobbi C et al (2018) Autoimmune liver disease serology in acute hepatitis E virus infection. J Autoimmun. https://doi.org/10.1016/j.jaut.2018.07.006 Vázquez-Abad D, Carson JH, Rothfield N (1996) Localization of histidyl-tRNA synthetase (Jo-1) in human laryngeal epithelial carcinoma cell line (HEp-2 cells). Cell Tissue Res 286:487–491. https://doi.org/10.1007/s004410050718 Gomard-Mennesson E, Fabien N, Cordier J-F et al (2007) Clinical significance of anti-histidyl-tRNA synthetase (Jo1) autoantibodies. Ann NY Acad Sci 1109:414–420. https://doi.org/10.1196/annals.1398.047 Alvarez F, Berg PA, Bianchi FB et al (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938 Hennes EM, Zeniya M, Czaja AJ et al (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48:169–176. https://doi.org/10.1002/hep.22322 Damoiseaux J, von Mühlen CA, Garcia-De La Torre I et al (2016) International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights 7:1. https://doi.org/10.1007/s13317-016-0075-0 Johnson GD, Holborow EJ, Glynn LE (1965) Antibody to smooth muscle in patients with liver disease. Lancet 2:878–879 Bottazzo GF, Florin-Christensen A, Fairfax A et al (1976) Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 29:403–410 Beretta-Piccoli BT, Mieli-Vergani G, Vergani D (2017) Serology in autoimmune hepatitis: a clinical-practice approach. Eur J Intern Med. https://doi.org/10.1016/j.ejim.2017.10.006 Muratori P, Muratori L, Agostinelli D et al (2002) Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity 35:497–500 Cassani F, Cataleta M, Valentini P et al (1997) Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 26:561–566. https://doi.org/10.1002/hep.510260305 Czaja AJ, Cassani F, Cataleta M et al (1996) Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24:1068–1073. https://doi.org/10.1002/hep.510240515 Liaskos C, Bogdanos D-P, Davies ET, Dalekos GN (2007) Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol 60:107–108. https://doi.org/10.1136/jcp.2006.039404 Granito A, Muratori L, Muratori P et al (2006) Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 59:280–284. https://doi.org/10.1136/jcp.2005.027367 Mieli-Vergani G, Vergani D, Baumann U et al (2017) Diagnosis and management of paediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr. https://doi.org/10.1097/MPG.0000000000001801 Beretta-Piccoli BT, Vergani D, Mieli-Vergani G (2018) Autoimmune sclerosing cholangitis: evidence and open questions. J Autoimmun. https://doi.org/10.1016/j.jaut.2018.10.008 Gregorio GV, Portmann B, Karani J et al (2001) Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 33:544–553. https://doi.org/10.1053/jhep.2001.22131 Rizzetto M, Swana G, Doniach D (1973) Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 15:331–344 Smith MG, Williams R, Walker G et al (1974) Hepatic disorders associated with liver-kidney microsomal antibodies. Br Med J 2:80–84 Homberg JC, Abuaf N, Bernard O et al (1987) Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of “autoimmune” hepatitis. Hepatology 7:1333–1339 Floreani A, Franceschet I, Cazzagon N et al (2015) Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol 48:192–197. https://doi.org/10.1007/s12016-014-8427-x Gregorio GV, Portmann B, Reid F et al (1997) Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 25:541–547. https://doi.org/10.1002/hep.510250308 Czaja AJ, Manns MP, Homburger HA (1992) Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103:1290–1295. https://doi.org/10.1016/0016-5085(92)91518-9 Manns MP, Johnson EF, Griffin KJ et al (1989) Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 83:1066–1072. https://doi.org/10.1172/JCI113949 Zanger UM, Hauri HP, Loeper J et al (1988) Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 85:8256–8260 Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F (1988) Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 168:801–806 Kerkar N, Ma Y, Davies ET et al (2002) Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays. J Clin Pathol 55:906–909 Kerkar N, Choudhuri K, Ma Y et al (2003) Cytochrome P4502D6(193–212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 170:1481–1489 Manns MP, Griffin KJ, Sullivan KF, Johnson EF (1991) LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 88:1370–1378. https://doi.org/10.1172/JCI115443 Yamamoto AM, Cresteil D, Homberg JC, Alvarez F (1993) Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 104:1762–1767 Vergani D, Mieli-Vergani G (2002) Autoimmunity after liver transplantation. Hepatology 36:271–276. https://doi.org/10.1053/jhep.2002.35339 Gilman AJ, Le AK, Zhao C et al (2018) Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations. BMJ Open Gastroenterol 5:e000203. https://doi.org/10.1136/bmjgast-2018-000203 Muratori L, Lenzi M, Ma Y et al (1995) Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 37:406–412 Ma Y, Peakman M, Lobo-Yeo A et al (1994) Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clin Exp Immunol 97:94–99. https://doi.org/10.1111/j.1365-2249.1994.tb06585.x Bogdanos D-P, Lenzi M, Okamoto M et al (2004) Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 17:83–92. https://doi.org/10.1177/039463200401700112 Bogdanos DP, Ma Y, Hadzic N et al (2004) P0295 virus-self crossreactivity inducing de novo autoimmune hepatitis eight-years after liver transplantation. J Pediatr Gastroenterol Nutr 39:S169 Kerkar N, Hadzić N, Davies ET et al (1998) De-novo autoimmune hepatitis after liver transplantation. Lancet 351:409–413. https://doi.org/10.1016/S0140-6736(97)06478-7 Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4:315–323 Homberg JC, Andre C, Abuaf N (1984) A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 55:561–570 Beaune P, Dansette PM, Mansuy D et al (1987) Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 84:551–555 Lecoeur S, André C, Beaune PH (1996) Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 50:326–333 Crivelli O, Lavarini C, Chiaberge E et al (1983) Microsomal autoantibodies in chronic infection with the HBsAg associated delta (delta) agent. Clin Exp Immunol 54:232–238 Strassburg CP, Obermayer-Straub P, Alex B et al (1996) Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 111:1576–1586 Philipp T, Durazzo M, Trautwein C et al (1994) Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 344:578–581 Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J (1990) Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 322:1829–1836. https://doi.org/10.1056/NEJM199006283222601 Clemente MG, Meloni A, Obermayer-Straub P et al (1998) Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 114:324–328 Martini E, Abuaf N, Cavalli F et al (1988) Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 8:1662–1666 Lapierre P, Hajoui O, Homberg JC, Alvarez F (1999) Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 116:643–649 Muratori L, Sztul E, Muratori P et al (2001) Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 34:494–501. https://doi.org/10.1053/jhep.2001.27179 Lenzi M, Manotti P, Muratori L et al (1995) Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 36:749–754 Rigopoulou EI, Mytilinaiou M, Romanidou O et al (2007) Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. J Autoimmune Dis 4:2. https://doi.org/10.1186/1740-2557-4-2 Han S, Tredger M, Gregorio GV et al (1995) Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology 21:58–62 Berg Stechemesser (1981) - Google Scholar. https://scholar.google.ch/scholar?hl=it&as_sdt=0,5&q=berg+stechemesser+1981. Accessed 20 Aug 2017 Stechemesser E, Strienz J, Berg PA (1987) Serological definition of new subgroup of patients with autoimmune chronic active hepatitis. Lancet 1:683 Stechemesser E, Klein R, Berg PA (1993) Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 18:1–9 Manns M, Gerken G, Kyriatsoulis A et al (1987) Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1:292–294 Ma Y, Okamoto M, Thomas MG et al (2002) Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 35:658–664. https://doi.org/10.1053/jhep.2002.32092 Wies I, Brunner S, Henninger J et al (2000) Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355:1510–1515 Volkmann M, Martin L, Bäurle A et al (2001) Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology 33:591–596. https://doi.org/10.1053/jhep.2001.22218 Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL (1992) Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci USA 89:9739–9743 Costa M, Rodríguez-Sánchez JL, Czaja AJ, Gelpí C (2000) Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients withtype-1 autoimmune hepatitis. Clin Exp Immunol 121:364–374 Herkel J, Heidrich B, Nieraad N et al (2002) Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology 35:403–408. https://doi.org/10.1053/jhep.2002.30699 Mix H, Weiler-Normann C, Thimme R et al (2008) Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis. Gastroenterology 135:2107–2118. https://doi.org/10.1053/j.gastro.2008.07.029 Zachou K, Weiler-Normann C, Muratori L et al (2020) Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar. Liver Int 40:368–376. https://doi.org/10.1111/liv.14280 van der Woude FJ, Rasmussen N, Lobatto S et al (1985) Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1:425–429 Falk RJ, Jennette JC (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318:1651–1657. https://doi.org/10.1056/NEJM198806233182504 Marzano AV, Raimondo MG, Berti E et al (2017) Cutaneous manifestations of ANCA-associated small vessels vasculitis. Clin Rev Allergy Immunol. https://doi.org/10.1007/s12016-017-8616-5 Terjung B, Herzog V, Worman HJ et al (1998) Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 28:332–340. https://doi.org/10.1002/hep.510280207 Hov JR, Boberg KM, Karlsen TH (2008) Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 14:3781–3791. https://doi.org/10.3748/wjg.14.3781 Roozendaal C, de Jong MA, van den Berg AP et al (2000) Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 32:734–741 Lindgren S, Nilsson S, Nässberger L et al (2000) Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J Gastroenterol Hepatol 15:437–442. https://doi.org/10.1046/j.1440-1746.2000.02078.x Terjung B, Söhne J, Lechtenberg B et al (2010) p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 59:808–816. https://doi.org/10.1136/gut.2008.157818 Targan SR, Landers C, Vidrich A, Czaja AJ (1995) High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 108:1159–1166 Zachou K, Rigopoulou E, Dalekos GN (2004) Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 1:2. https://doi.org/10.1186/1740-2557-1-2 Hov JR, Boberg KM, Taraldsrud E et al (2017) Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis. Liver Int 37:458–465. https://doi.org/10.1111/liv.13238 Yoshida A, Matsuoka K, Ueno F et al (2021) Serum PR3-ANCA is a predictor of primary nonresponse to anti-TNF-α agents in patients with ulcerative colitis. Inflamm Intest Dis 6:117–122. https://doi.org/10.1159/000515361 Leung PSC, Rossaro L, Davis PA et al (2007) Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 46:1436–1442. https://doi.org/10.1002/hep.21828 Couto CA, Bittencourt PL, Porta G et al (2014) Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis. Hepatology 59:592–600. https://doi.org/10.1002/hep.26666 Kroshinsky D, Stone JH, Bloch DB, Sepehr A (2009) Case records of the Massachusetts General Hospital. Case 5–2009. A 47-year-old woman with a rash and numbness and pain in the legs. N Engl J Med 360:711–720. https://doi.org/10.1056/NEJMcpc0807822 Pisetsky DS (2017) Antinuclear antibody testing—misunderstood or misbegotten? Nat Rev Rheumatol 13:495–502. https://doi.org/10.1038/nrrheum.2017.74